Clinical Study | Office of Clinical Research

Constellation 0209-01 A Phase 1/2 Study Of Cpi-0209 Monotherapy And In Combination With Other Therapy In Patients With Advanced Tumors

Posted Date: Jul 13, 2021

Investigator: Shuchi Gulati
Specialties: Cancer, Oncology
Type of Study: Drug

The primary objective of this study is to study CPI-0209 in patients with advanced tumors alone and in combination with other therapies. CPI-0209 is a small molecule inhibitor of EZH2. Efficacy will be measured by Frequency of Dose-limiting toxicities.

Criteria:

Recovered To Baseline Or Grade = 1 Severity From Toxicity Related To Prior Treatments, Unless Aes Are Clinically Non-Significant And/Or Stable On Supportive Therapy. Ecog 0-1. Adequate Bone Marrow Function. Adequate Renal Function. Adequate Liver Function

Keywords:

Phase 1

For More Information:

Uc Cancer Center
5135847698
cancer@uchealth.com

Name*
First Last
Gender*
- Male
- Female
Age*
Phone*
Email*
How did you hear about us?*
Future Communication*
- By submitting this form, I am agreeing to receive future communication about participating in an upcoming research study.
CAPTCHA
This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.
List